XDR-Klebsiella pneumoniae isolates harboring blaOXA-48: In vitro and in vivo evaluation using a murine thigh-infection model

被引:3
|
作者
Kamel, Noha A. [1 ]
El-Tayeb, Wafaa N. [1 ]
El-Ansary, Mona R. [2 ]
Mansour, Mohamed T. [3 ]
Aboshanab, Khaled M. [4 ]
机构
[1] Misr Int Univ, Fac Pharm, Dept Microbiol, Cairo 9648, Egypt
[2] Modern Univ Technol & Informat, Dept Biochem, Cairo 11566, Egypt
[3] Cairo Univ, Dept Virol & Immunol, Childrens Canc Hosp 57357, Cairo 19057, Egypt
[4] Ain Shams Univ, Fac Pharm, Dept Microbiol & Immunol, Cairo 11566, Egypt
关键词
Carbapenemases; Klebsiella pneumoniae; antibiotic combination; murine thigh model; extensively drug-resistant; bla(OXA-48); CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; COLISTIN; EFFICACY; THERAPY; SPREAD;
D O I
10.1177/1535370219886826
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Blood stream infection with extensively drug-resistant-carbapenamase producing Klebsiella (K.) pneumoniae usually represents a major threat with medical challenges among hospitalized cancer patients with poor functional status and underlying diseases. Accordingly, the aim of the study was to evaluate the efficacy of different antibiotics either alone or in combinations against extensively drug-resistant-OXA-48 producing K. pneumoniae clinical isolates that were previously recovered from febrile neutropenic pediatric cancer patients. The antimicrobial activity of amikacin, gentamicin, colistin, ertapenem, imipenem, meropenem and tigecycline was assessed by broth microdilution method. The results revealed that all the tested OXA-48 producing K. pneumoniae isolates exhibited extensively drug-resistant phenotype and all of them were susceptible to tigecycline. Checkerboard method was used to determine the fraction inhibitory concentration index, to further classify the effect of antibiotic combination as synergistic, additive, indifferent, or antagonistic effect. The results revealed that in vitro dual carbapenem combination of ertapenem with meropenem had shown synergistic effect against all of the tested isolates. Additionally, synergistic effect of meropenem with colistin was detected among three of four isolates tested. Herein we investigated the in vivo activity of colistin, meropenem alone and in combination in a rat thigh infection model. The results showed that addition of meropenem to colistin was not effective at reduction of bacterial count as compared to colistin alone at 24 h post treatment. Accordingly, we can conclude that in vitro antibiotic combinations of dual carbapenems (ertapenem plus meropenem) and meropenem plus colistin showed synergism in 100% and 75% of the tested isolates, respectively. Colistin alone had significantly reduced bacterial count while its combination with meropenem was not superior to monotherapy in murine thigh infection model. Impact statement The present study aimed to evaluate the effectiveness of various antibiotics both in vitro and in vivo using murine animal model either alone or in combination against various strains of extensively drug-resistant (XDR) Klebsiella pneumoniae, life-threatening pathogens of relevant medical importance isolated from febrile neutropenic pediatric cancer patients. This work also emphasizes how to select the appropriate antibiotics options and help the physicians to choice the appropriate antibiotic for the treatment of such superbugs (extensively drug-resistant (XDR) Klebsiella pneumoniae). The results showed that in vitro dual carbapenem combination of ertapenem with meropenem had shown synergistic effect against all of the tested XDR isolates. Antibiotic combinations of dual carbapenems and meropenem plus colistin showed synergism in 100% and 75% of the testes isolates, respectively. Results of the in vivo evaluation, colistin alone had significantly reduced bacterial count while its combination with meropenem was not superior to monotherapy.
引用
收藏
页码:1658 / 1664
页数:7
相关论文
共 11 条
  • [1] Genomic analysis of extensively drug resistant (XDR) Klebsiella pneumoniae high-risk clone ST14 co-harboring blaNDM and blaOXA-48 recovered from Saudi Arabia
    Al-Zahrani, Ibrahim A.
    Aljabri, Ahmed
    Alhazmi, Wafaa A.
    Yasir, Muhammad
    Abujamel, Turki
    Alghamdi, Ahmed K.
    Azhar, Esam I.
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2024, 17 (04) : 669 - 675
  • [2] Pharmacokinetic and Pharmacodynamic Evaluation of P-873 versus Klebsiella pneumoniae in a Neutropenic Murine Thigh Infection Model
    Lamb, Lucinda M.
    Crandon, Jared L.
    Nicolau, David P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) : 1971 - 1973
  • [3] Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model
    Hagihara, Mao
    Kato, Hideo
    Sugano, Toshie
    Okade, Hayato
    Sato, Nobuo
    Shibata, Yuichi
    Sakanashi, Daisuke
    Asai, Nobuhiro
    Koizumi, Yusuke
    Suematsu, Hiroyuki
    Yamagishi, Yuka
    Mikamo, Hiroshige
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2021, 57 (05)
  • [4] In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model
    Zhao, Miao
    Lepak, Alexander J.
    Marchillo, Karen
    VanHecker, Jamie
    Andes, David R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (09)
  • [5] In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
    Lepak, Alexander J.
    Zhao, Miao
    VanScoy, Brian
    Taylor, Daniel S.
    Ellis-Grosse, Evelyn
    Ambrose, Paul G.
    Andes, David R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (06)
  • [6] In vitro evaluation of double-carbapenem combinations against OXA-48-producing Klebsiella pneumoniae isolates using time-kill studies
    Galani, Irene
    Nafplioti, Konstantina
    Chatzikonstantinou, Marianthi
    Souli, Maria
    JOURNAL OF MEDICAL MICROBIOLOGY, 2018, 67 (05) : 662 - 668
  • [7] Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model
    Sho Tashiro
    Marina Hayashi
    Wataru Takemura
    Yuki Igarashi
    Xiaoxi Liu
    Yuki Mizukami
    Nana Kojima
    Yuki Enoki
    Kazuaki Taguchi
    Yuta Yokoyama
    Tomonori Nakamura
    Kazuaki Matsumoto
    Pharmaceutical Research, 2021, 38 : 27 - 35
  • [8] Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model
    Tashiro, Sho
    Hayashi, Marina
    Takemura, Wataru
    Igarashi, Yuki
    Liu, Xiaoxi
    Mizukami, Yuki
    Kojima, Nana
    Enoki, Yuki
    Taguchi, Kazuaki
    Yokoyama, Yuta
    Nakamura, Tomonori
    Matsumoto, Kazuaki
    PHARMACEUTICAL RESEARCH, 2021, 38 (01) : 27 - 35
  • [9] In vitro assays for clinical isolates of sequence type 131 Escherichia coli do not recapitulate in vivo infectivity using a murine model of urinary tract infection
    Rudick, Courtney P.
    Cox, Rachel S.
    Bourret, Travis J.
    Hanson, Nancy D.
    MICROBIOLOGY SPECTRUM, 2025,
  • [10] In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model
    Monogue, M. L.
    Abbo, L. M.
    Rosa, R.
    Camargo, J. F.
    Martinez, O.
    Bonomo, R. A.
    Nicolau, D. P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (07)